STAAR Surgical Company (STAA)
NASDAQ: STAA · Real-Time Price · USD
17.66
+0.43 (2.50%)
At close: Mar 11, 2026, 4:00 PM EDT
17.49
-0.17 (-0.96%)
After-hours: Mar 11, 2026, 7:59 PM EDT

Company Description

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.

The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists.

The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.

STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Company
STAAR Surgical Company logo
CountryUnited States
Founded1982
IndustryMedical Instruments & Supplies
SectorHealthcare
Employees1,157
CEOStephen Farrell

Contact Details

Address:
25510 Commercentre Drive
Lake Forest, California 92630
United States
Phone626 303 7902
Websitestaar.com

Stock Details

Ticker SymbolSTAA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearFebruary - January
Reporting CurrencyUSD
CIK Code0000718937
CUSIP Number852312305
ISIN NumberUS8523123052
Employer ID95-3797439
SIC Code3851

Key Executives

NamePosition
Deborah J. AndrewsInterim Co-Chief Executive Officer and Chief Financial Officer
Warren FoustInterim Co-Chief Executive Officer, President and Chief Operating Officer
Dr. Magda Michna Ph.D.Chief Development Officer
Nathaniel B. Sisitsky Esq.Consultant
Nancy SabinChief Marketing Officer
Dr. Scott D. Barnes M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Mar 3, 20268-KCurrent Report
Mar 3, 202610-KAnnual Report
Feb 5, 20268-KCurrent Report
Feb 2, 20268-KCurrent Report
Jan 16, 2026SCHEDULE 13D/AFiling
Jan 16, 2026SCHEDULE 13D/AFiling
Jan 16, 20268-KCurrent Report
Jan 15, 20268-KCurrent Report
Jan 8, 2026SCHEDULE 13D/AFiling
Jan 6, 20268-KCurrent Report